JAMES MAGUIRE: Open Payments
NPI 1811006091 · LEWISTON, ID. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$650 in 40 payments from 7 companies in 2025. Trend: 2023 $32 · 2024 $401 · 2025 $650
Food & beverage: $650
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 13 | $228 |
| GlaxoSmithKline, LLC. | 21 | $201 |
| AstraZeneca Pharmaceuticals LP | 2 | $144 |
| Otsuka America Pharmaceutical, Inc. | 1 | $23 |
| PFIZER INC. | 1 | $22 |
| Amgen Inc. | 1 | $18 |
| Abbott Laboratories | 1 | $15 |
Products named: TRELEGY ELLIPTA, BREZTRI, UBRELVY, QULIPTA, VRAYLAR, REXULTI, NURTEC ODT, OTEZLA.
Industry payments across ID — which companies pay providers there.
